Pramlintide improved glycaemic control and reduced weight in patients with type 2 diabetes treating to target with basal insulin

被引：0

作者：

Wilhelm, K. ^{[1
]}

Riddle, M. ^{[2
]}

Zhang, B. ^{[1
]}

Maier, H. ^{[1
]}

Kolterman, O. ^{[1
]}

机构：

[1] Amylin Pharmaceut, San Diego, CA USA

[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA

来源：

DIABETOLOGIA | 2008年 / 51卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1011

引用

页码：S409 / S409

页数：1

共 50 条

[1] Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes treating to target with basal insulin
Riddle, Matthew
Zhang, Bei
Maier, Holly
Wilhelm, Ken
Kolterman, Orville
DIABETES, 2008, 57 : A156 - A156
[2] Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin
Riddle, Matthew
Frias, Juan
Zhang, Bei
Maier, Holly
Brown, Carl
Lutz, Karen
Kolterman, Orville
DIABETES CARE, 2007, 30 (11) : 2794 - 2799
[3] Pramlintide improved glycemic control and reduced body weight in patients with type 2 diabetes treated with basal insulin (without mealtime insulin) and a thiazolidinedione
Lorenzi, Gayle
Frias, Juan
Lutz, Karen
Kesty, Nicole
Zhang, Bei
Kolterman, Orville
DIABETES, 2007, 56 : A147 - A147
[4] Pramlintide improved glycaemic control and reduced weight without increased hypoglycaemia in patients with type 2 diabetes inadequately controlled with insulin glargine ± oral agents
Riddle, M.
Brown, C.
Zhang, B.
Maier, H.
Lutz, K.
Maggs, D.
Kolterman, O.
DIABETOLOGIA, 2007, 50 : S375 - S376
[5] Pramlintide, as an adjunct to basal insulin, reduced C-reactive protein, improved glycemic control, and led to weight loss in patients with type 2 diabetes
Lush, Cameron
Frias, Juan
Zhang, Bei
Maier, Holly
Kolterman, Orville
DIABETES, 2007, 56 : A144 - A144
[6] Pramlintide improved glycemic control without increased risk of hypoglycemia in patients with type 2 diabetes using basal insulin
Lutz, Karen
Maier, Holly
Zhang, Bei
Frias, Juan
DIABETES, 2007, 56 : A143 - A143
[7] Pramlintide or mealtime insulin added to basal insulin treatment in patients with type 2 diabetes
Riddle, M.
Pencek, R.
Charenkavanich, S.
Lutz, K.
Porter, L.
Wilhelm, K.
DIABETOLOGIA, 2008, 51 : S407 - S408
[8] Pramlintide improved glycemic control and reduced weight without increased hypoglycemia in patients with type 2 diabetes inadequately controlled with insulin glargine ± oral agents
Riddle, Matthew
Brown, Carl
Zhang, Bei
Maier, Holly
Lutz, Karen
Frias, Juan
Kolterman, Orville
DIABETES, 2007, 56 : A143 - A144
[9] Combining insulin glulisine with basal insulin glargine provides improved glycaemic control in patients with Type 2 diabetes in everyday clinical practice
Donaubauer, B.
Ferlinz, K.
Schreiber, S.
DIABETIC MEDICINE, 2008, 25
[10] Pramlintide as an adjunct to insulin glargine reduced A1C and body weight in patients with type 2 diabetes
Frias, Juan
Bei, Zhang
Darsow, Tamara
DIABETES, 2006, 55 : A112 - A112

← 1 2 3 4 5 →